Free Trial
NASDAQ:ITOS

iTeos Therapeutics Q1 2025 Earnings Report

iTeos Therapeutics logo
$7.77 +0.27 (+3.60%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$7.77 0.00 (0.00%)
As of 05/2/2025 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iTeos Therapeutics EPS Results

Actual EPS
-$0.80
Consensus EPS
-$0.94
Beat/Miss
Beat by +$0.14
One Year Ago EPS
N/A

iTeos Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$9.35 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

iTeos Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Monday, April 28, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

iTeos Therapeutics' Q2 2025 earnings is scheduled for Friday, May 9, 2025

iTeos Therapeutics Earnings Headlines

Q2 EPS Estimates for iTeos Therapeutics Reduced by Wedbush
Q2 EPS Forecast for iTeos Therapeutics Lifted by Analyst
Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.
See More iTeos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iTeos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iTeos Therapeutics and other key companies, straight to your email.

About iTeos Therapeutics

iTeos Therapeutics (NASDAQ:ITOS) is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

View iTeos Therapeutics Profile

More Earnings Resources from MarketBeat